Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
Special Report
Novartis MD: Time to embrace change
He has taken the helm at a time when many in the industry are concerned for the future but Novartis head Brian Gladsden says it is time to move forward, rebuild relationships with stakeholders and embrace change.
Open Forum
Time to get subjective about drugs
The highly objective approach to determining the effectiveness of drugs embodied in clinical trials comes under question from an Australian doctor and mathematician who says it may rule out useful treatments unnecessarily.
Pipeline Monitor
Regulators in a generous mood
The FDA and the EMA have been busy approving and recommending new cancer, HIV and heart failure drugs.
Working Life
Staff rate managers in industry survey
Managers in Australian pharma companies have been given a positive report card from staff in the latest industry survey, although there are significant differences between branded only, generic only and combination companies.
Approvals Action
First competitor for narcolepsy drug
The first generic competitor for Teva'smulti-million dollar narcolepsy drug Modavigil has arrived on the PBS along with a raft of additions to already listed generics.